Related Experiment Video
Updated: Oct 31, 2025

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia: A Cohort Study
Daniel Echeverría-Esnal1,2, Luisa Sorli2,3, Nuria Prim4
1Pharmacy Department, Hospital del Mar, Passeig Maritim 25-29, 08003 Barcelona, Spain.
Background:
Ampicillin resistant and glycopeptide susceptible Enterococcus faecium bloodstream infection (GSEF-BSI) incidence has risen. However, the treatment of choice remains unknown. Daptomycin use for the treatment of enterococcal infections has increased, despite effectiveness and safety concerns. The objective was to compare the effectiveness and safety of daptomycin and glycopeptides in the treatment of GSEF-BSI.
Methods:
This was a single-centre, retrospective observational cohort study performed at Hospital del Mar (Barcelona, Spain), from January 2006-May 2018. The primary outcome was clinical cure at the end of the therapy, and secondary outcomes included 14-day, 30-day, in-hospital mortality, and length of stay.
Results:
From a total of 192 patients with GSEF-BSI, 54 (28.1%) were treated with glycopeptides and 17 (8.9%) with daptomycin. Patients treated with daptomycin presented a lower clinical cure than patients treated with glycopeptides (58.8% vs. 83.3%, RR 0.416 (95% CI 0.189-0.915)). After controlling for confounding variables by means of multivariate analysis the significative difference was confirmed (aOR 4.313, 95% CI, 1.053-17.660). The need for treatment discontinuation due to adverse events was similar.
Conclusions:
Patients with GSEF-BSI treated with glycopeptides showed a higher clinical cure than those treated with daptomycin.
More Related Videos
07:50Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
08:37The Application of Open Searching-based Approaches for the Identification of Acinetobacter baumannii O-linked Glycopeptides
Published on: November 2, 2021
Related Concept Videos
Antimicrobial Effectiveness
Acute Pyelonephritis II: Diagnostic Studies and Management
Estimation of k and VD of Aminoglycosides
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence